

***Incidence And Predictotrs Of Bleeding  
Among Patients With Acute Coronary Syndrome  
Using The CRUSADE risk score .***

Thesis

Submitted For Partial Fulfillment of Master Degree in Cardiology

Presented by

***Maikel Nabil Peniameen***

**M.B.,B.CH.**

*Under the supervision of*

***Prof.Dr. Sameh Mammoun Shaheen.***

Professor of Cardiology  
Faculty of medicine  
Ain shams University

***Dr. Ayman Morttada Abd El-Moteleb.***

Assisitant professor of Cardiology  
Faculty of medicine  
Ain shams University

Faculty of medicine

Ain shams university

2015





*First of all, all gratitude is due to **God** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.*

*Really I can hardly find the words to express my gratitude to **Prof. Dr. Sameh Shaheen**, Professor of cardiology, faculty of medicine, Ain Shams University, for his supervision, continuous help, encouragement throughout this work and tremendous effort he has done in the meticulous revision of the whole work. It is a great honor to work under his guidance and supervision*

*I would like also to express my sincere appreciation and gratitude to **Dr. Ayman Morttada**, assistant professor of cardiology, faculty of medicine, Ain Shams University, for his continuous directions and support throughout the whole work. whom I considered an older brother rather than a supervisor.*

*Last but not least, I dedicate this work to my family, whom without their sincere emotional support, pushing me forward this work would not have ever been completed.*



**Maikel Nabil peniameen**



## List of contents

• List of abbreviations	iii
• List of tables	vi
• List of figures	vii
• Introduction	1
• Aim of the work	3
• Review of literature	
- Chapter 1: Acute Coronary Syndrome .	4
- Chapter 2: Treatment approaches for acute coronary syndromes , Antiplatelets, antithrombotics,thrombolytics and PCI.	23
- Chapter 3: Bleeding and acute coronary syndrome	49
• Patients and methods	73
• Results	80
• Discussion	98
• Conclusion and recommendations	108
• Summary	110
• Study limitations	112
• References	113
• Master sheet	132
• Arabic summary	162



## List of Abbreviations

- ACC American College of Cardiology
- ACAD Atherosclerotic coronary artery disease
- ACS Acute coronary syndrome
- ACUITY Acute Catheterization and Urgent Intervention/Triage Strategy trial
- ADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-term Follow-up
- AHA American Heart Association
- APRICOT Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis
- ASPECT Anticoagulation in the Secondary Prevention of Events in Coronary Thrombosis
- BRAVE Bavarian Reperfusion Alternatives Evaluation
- CABG Coronary artery bypass grafting
- CAD Coronary artery disease
- CHD Coronary heart disease
- CHF Congestive heart failure
- CI Confidence interval
- Cr. Cl. Creatinine clearance
- CCU Coronary Care Unit
- CREDO Clopidogrel for Reduction of Events During Observation
- CRP C-Reactive Protein
- COMMIT The Clopidogrel and Metoprolol in Myocardial Infarction Trial
- CURE Clopidogrel in Unstable angina to prevent Recurrent ischemic Events
- CVD Cardiovascular disease
- DAPT Dual antiplatelet therapy
- DM Diabetes mellitus
- DES Drug-eluting stent
- D1 First diagonal branch
- ECG Electrocardiogram
- ESSENCE Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events

- FEM Femoral approach
- GIB Gastrointestinal bleeding
- GPII b/IIIa Glycoprotein IIb/IIIa inhibitor
- GRACE Global Registry of Acute Coronary Events
- GUSTO Global Use of Strategy To Open Occluded coronary arteries
- HTN Hypertension
- IRA Ischemia-Related Artery
- ISAR-REACT Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary treatment
- ISR Instent restenosis
- LAD Left anterior descending artery
- LCX Left circumflex artery
- LIMA Left internal mammary artery
- LM Left main coronary artery
- MERLIN Middlesbrough early revascularisation to limit Infarction
- MVD Multi-vessel disease
- MI Myocardial infarction
- MOD Moderate
- NSTEMI Non ST segment elevation myocardial infarction
- OASIS Organization to Assess Strategies in Ischemic Symptoms
- OMB1 First obtuse marginal branch
- OMB2 Second obtuse marginal branch
- PAD Peripheral arterial disease
- PAI-1 Plasminogen activator inhibitor
- PCI Percutaneous coronary intervention
- PCI-CURE Clopidogrel in Unstable angina to prevent Recurrent ischemic Events in patients undergoing Percutaneous Coronary Intervention
- PLATO The platelet inhibition and patient outcomes
- PRISM Platelet Receptor Inhibition in Ischemic Syndrome Management
- PRISM-PLUS Platelet Receptor inhibition in Ischemic Syndrome and symptoms management in Patients Limited by Unstable Signs
- PDA Posterior descending artery
- PTCA Percutaneous trans luminal coronary angioplasty



- PURSUIT      Platelet IIB/IIIa Underpinning the Receptors for  
Suppression of Unstable Ischemia Trial.
- RAD           Radial approach
- RCA           Right coronary artery
- RCT           Randomized control trials
- RI             Ramus intermediate branch
- STEMI        ST segment elevation myocardial infarction
- SVG           Saphenous venous graft
- TACTICS      The Treat Angina with Aggrastat and determine  
Cost of Therapy with an Invasive or Conservative  
Strategy
- TIA           Transient ischemic attack
- TIMI          Thrombolysis In Myocardial Infarction
- TnI            Troponin I
- TNK           Tenecteplase
- TnT            Troponin T
- tPA            Tissue type plasminogen activator
- UA             Unstable Anginae
- UFH           Unfractionated Heparine



## List of tables

Table No.	Title	Page number
1	Braunwald clinical classification of unstable angina.	9
2	TIMI risk score system.	22
3	Preferred strategy according to the patient characteristics .	22
4	Comparison of ESC & ACC/AHA guidelines recommendation for anti-coagulation.	33
5	Diagnostic tools used to evaluate tissue and micro vascular occlusion perfusion in patient with STEMI	37-38
6	Highlights of differences in dosing, pharmacokinetics, recanalization rate and cost between thrombolytic agents.	39-40
7	Commonly used bleeding classification in clinical trials.	51-52
8	Independent factors of nuisance bleeding.	57
9	Predictors of bleeding in RCT.	69
10	Pharmacotherapy strategy of each ischemic and bleeding scores .	70
11	Comparison between bleeders and non bleeders regarding selected quantitative variables.	83
12	Comparison between bleeders and non bleeders regarding selected qualitative variables.	84
13	Description of the catheterization procedure in bleeders and non bleeders.	86
14	Absolute and relative risk of bleeding in different levels of CRUSADE risk score.	90
15	Absolute risk of mild and moderate bleeding in different levels of CRUSADE risk score.	91
16	Incidence of bleeding by site at different levels of CRUSADE risk score.	93
17	Bleeding sites of all cases.	93

## List of figures

Fig. No.	Title	Page No.
<b>1.1</b>	Platelet Adhesion.	12
<b>1.2</b>	Activation of coagulation system.	13
<b>2.1</b>	Antiplatelet drug target.	29
<b>2.2</b>	Mechanism of action of various anti-platelets.	33
<b>2.3</b>	Algorithm for reperfusion therapy.	39
<b>4.1</b>	Figure showing different sex categories percentage in the study.	80
<b>4.2</b>	Figure showing risk factors profile in the study population.	81
<b>4.3</b>	Figure showing percentage of CHF patients among the study population.	82
<b>4.4</b>	Figure showing different clinical presentations in the study population.	82
<b>4.5</b>	Figure showing percentages of different medications administered during hospital admission.	84
<b>4.6</b>	Figure showing that more patients undergoing invasive strategy had experienced bleeding events.	87
<b>4.7</b>	Figure showing that that most of our patients had undergone femoral approach .	87
<b>4.8</b>	Figure showing different coronary angiogram findings	88
<b>4.9</b>	Figure showing different recommendation of coronary angiogram.	88
<b>4.10</b>	Figure showing increased incidence of bleeding as the risk had increased.	89
<b>4.11</b>	Figure showing increased incidence of bleeding in the different CRUSADE risk score groups.	90
<b>4.12</b>	Figure showing mild and moderate bleeding in different risk groups.	92
<b>4.13</b>	Figure showing incidence of bleeding in the study participants.	94
<b>4.14</b>	Figure showing that more females rather than males are bleeders.	94
<b>4.15</b>	Figure showing that more diabetic patients had experienced bleeding events.	95
<b>4.16</b>	Figure showing more patients with prior vascular disease had experienced bleeding events.	95
<b>4.17</b>	Figure showing that bleeding had increased with severity, acuity of presentation.	96

<b>4.18</b>	Figure showing that more patients with CHF had experienced bleeding events.	97
<b>4.19</b>	Figure showing that more patients administrating this drug had experienced bleeding events.	97



**I ntroduction**

**&**

**A im of the  
work**